|
|
|
|
| LEADER |
00000cam a2200000Ma 4500 |
| 001 |
SCIDIR_ocn830164760 |
| 003 |
OCoLC |
| 005 |
20231117032946.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
130316s1984 flua ob 001 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCQ
|d N$T
|d OCLCE
|d E7B
|d OPELS
|d OCLCF
|d OCLCQ
|d UKDOC
|d UIU
|d OCLCQ
|d UA@
|d YDXCP
|d OCL
|d OCLCQ
|d MERUC
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCA
|d OCLCQ
|d OCLCA
|d LEAUB
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCQ
|
| 019 |
|
|
|a 567805985
|a 638000541
|a 638000567
|a 974619916
|
| 020 |
|
|
|a 9780323141987
|q (electronic bk.)
|
| 020 |
|
|
|a 0323141986
|q (electronic bk.)
|
| 020 |
|
|
|z 0120446200
|q (alk. paper)
|
| 020 |
|
|
|z 9780120446209
|q (alk. paper)
|
| 035 |
|
|
|a (OCoLC)830164760
|z (OCoLC)567805985
|z (OCoLC)638000541
|z (OCoLC)638000567
|z (OCoLC)974619916
|
| 042 |
|
|
|a dlr
|
| 050 |
|
4 |
|a RM666.C266
|b C36 1984eb
|
| 060 |
|
4 |
|a QV 77.7
|b C2246 1982
|
| 072 |
|
7 |
|a MED
|x 093000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 105020
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615.7827
|2 19
|
| 245 |
0 |
4 |
|a The cannabinoids :
|b chemical, pharmacologic, and therapeutic aspects /
|c edited by Stig Agurell, William L. Dewey, Robert E. Willette.
|
| 260 |
|
|
|a Orlando, FL :
|b Academic Press,
|c 1984.
|
| 300 |
|
|
|a 1 online resource (xxii, 909 pages) :
|b illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 506 |
|
|
|3 Use copy
|f Restrictions unspecified
|2 star
|5 MiAaHDL
|
| 533 |
|
|
|a Electronic reproduction.
|b [Place of publication not identified] :
|c HathiTrust Digital Library,
|d 2010.
|5 MiAaHDL
|
| 538 |
|
|
|a Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.
|u http://purl.oclc.org/DLF/benchrepro0212
|5 MiAaHDL
|
| 583 |
1 |
|
|a digitized
|c 2010
|h HathiTrust Digital Library
|l committed to preserve
|2 pda
|5 MiAaHDL
|
| 588 |
0 |
|
|a Online resource; title from pdf information screen (Ebsco, viewed May 20, 2013).
|
| 505 |
0 |
|
|a Front Cover; The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects; Copyright Page; Table of Contents; Contributors; Preface; Section I: CLINICAL ASPECTS; Chapter 1. HEALTH ASPECTS OF CANNABIS USE; I. INTRODUCTION; II. ADVERSE EFFECTS ON HEALTH; III. THERAPEUTIC ASPECTS; IV. SUMMARY; REFERENCES; Chapter 2. MARIJUANA: ACUTE EFFECTS ON HUMAN MEMORY; I. INTRODUCTION; II. METHODS AND RESULTS; III. MARIJUANA AND MEMORY -- AN INTEGRATIVE ASSESSMENT; REFERENCES; Chapter 3. CHARACTERISTICS, BEHAVIORS, AND OUTCOMES FOR MARIJUANA USERS SEEKING TREATMENT IN DRUG ABUSE TREATMENT PROGRAM.
|
| 505 |
8 |
|
|a I. INTRODUCTIONII. METHODS; III. RESULTS; IV. DISCUSSION; REFERENCES; Section II: CHEMICAL ASPECTS; Chapter 4. CHMISTRY AND STRUCTURE-ACTIVITY RELATIONSHIPS OF CANNABINOIDS: AN OVERVIEW; I. INTRODUCTION; II. SYNTHESIS; III. METABOLITES OF TETRAHYDROCANNABINOLS; IV. SAR IN CANNABINOIDS; REFERENCES; Chapter 5. SEPARATION OF ACID AND NEUTRAL CANNABINOIDS IN CANNABIS SATIVA L. USING HPLC; I. INTRODUCTION; II. MATERIALS AND METHODS; Chapter 8. SEPARATION OF ACID AND NEUTRAL CANNABINOIDS IN CANNABIS SATIVA L. USING HPLC; I. INTRODUCTION; II. MATERIALS AND METHODS; III. RESULTS AND DISCUSSION.
|
| 505 |
8 |
|
|a III. RESULTS AND DISCUSSIONIV. COMMENTS AND CONCLUSIONS; IV. COMMENTS AND CONCLUSIONS; REFERENCES; REFERENCES; Chapter 6. CONSTITUENTS OF CANNABIS SATIVA L. XXIIII: CANNABITETRCL, A NEW POLYHYDROXYLATED CANNABINOID; I. INTRODUCTION; Chapter 9. CONSTITUENTS OF CANNABIS SATIVA L. XXIIII: CANNABITETRCL, A NEW POLYHYDROXYLATED CANNABINOID; I. INTRODUCTION; II. EXPERIMENTAL; II. EXPERIMENTAL; III. DISCUSSION; III. DISCUSSION; REFERENCES; REFERENCES; Chapter 7. SOME SMOKING CHARACTERISTICS OF MARIJUANA CIGARETTES; I. INTRODUCTION; Chapter 10. SOME SMOKING CHARACTERISTICS OF MARIJUANA CIGARETTES.
|
| 505 |
8 |
|
|a I. INTRODUCTIONII. MATERIALS AND METHODS; II. MATERIALS AND METHODS; III. RESULTS; III. RESULTS; IV. DISCUSSION; IV. DISCUSSION; ACKNOWLEDGMENTS; REFERENCES; ACKNOWLEDGMENTS; REFERENCES; Chapter 11. AN AUTOMATED COMPUTER-BASED SYSTEM FOR TOE STUDY OF MARIJUANA SMOKING DYNAMICS; I. INTRODUCTION; II. METHODS; III. CONCLUSIONS; REFERENCES; Chapter 12. DEVELOPMENTS IN CANNABINOID ANALYSES OF BODY FLUIDS: IMPLICATIONS FOR FORENSIC APPLICATIONS; I. INTRODUCTION; II. ANALYTICAL FACTORS; III. SOCIETAL FACTORS; IV. DISCUSSION; REFERENCES.
|
| 505 |
8 |
|
|a Chapter 13. RADIOIMMUNOASSAY FOR 11-HYDROXY-DELTA-9-TETRAHYDROCANNABINOL, MAJOR PSYCHOACTIVE METABOLITE OF DELTA-9-TETRAHYDROCANNABINOLI. INTRODUCTION; II. RESULTS AND DISCUSSION; REFERENCES; Chapter 14. NOVEL DERIVATIZATION METHODS IN THE ANALYSIS OF CANNABINOIDS; I. INTRODUCTION; II. LIQUID/LIQUID BIPHASIC BENZYLATION REACTIONS; III. AUTOMATION OF CHEMICAL PROCESSES; IV. SOLID PHASE SYNTHESIS; V. SUMMARY; REFERENCES; Section III: METABOLIC AND PHARMACOKINETIC ASPECTS; Chapter 15. RECENT STUDIES ON THE PHARMACOKINETICS OF DELTA-1-TETRAHYDROCANNABINOL IN MAN; I. INTRODUCTION; II. METHODS.
|
| 650 |
|
0 |
|a Cannabinoids
|v Congresses.
|
| 650 |
|
0 |
|a Tetrahydrocannabinol
|v Congresses.
|
| 650 |
|
0 |
|a Cannabinoids
|x Congresses.
|
| 650 |
|
0 |
|a Tetrahydrocannabinol
|x Congresses.
|
| 650 |
|
2 |
|a Cannabinoids
|x adverse effects
|0 (DNLM)D002186Q000009
|
| 650 |
|
2 |
|a Cannabinoids
|x pharmacology
|0 (DNLM)D002186Q000494
|
| 650 |
|
2 |
|a Cannabis
|0 (DNLM)D002188
|
| 650 |
|
6 |
|a Cannabino�ides
|0 (CaQQLa)201-0078335
|x Congr�es.
|0 (CaQQLa)201-0378208
|
| 650 |
|
6 |
|a T�etrahydrocannabinol
|0 (CaQQLa)201-0078334
|x Congr�es.
|0 (CaQQLa)201-0378208
|
| 650 |
|
6 |
|a Cannabino�ides
|0 (CaQQLa)201-0078335
|v Congr�es.
|0 (CaQQLa)201-0378219
|
| 650 |
|
6 |
|a T�etrahydrocannabinol
|0 (CaQQLa)201-0078334
|v Congr�es.
|0 (CaQQLa)201-0378219
|
| 650 |
|
7 |
|a MEDICAL
|x Pain Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Psychiatry
|x Psychopharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Cannabinoids.
|2 fast
|0 (OCoLC)fst00845733
|
| 650 |
|
7 |
|a Tetrahydrocannabinol.
|2 fast
|0 (OCoLC)fst01148400
|
| 650 |
|
7 |
|a Cannabino�ides
|x effets ind�esirables.
|2 fmesh
|
| 650 |
|
7 |
|a Cannabino�ides
|x Pharmacologie.
|2 fmesh
|
| 650 |
|
7 |
|a Cannabis.
|2 fmesh
|
| 655 |
|
2 |
|a Congress
|0 (DNLM)D016423
|
| 655 |
|
7 |
|a Conference papers and proceedings.
|2 fast
|0 (OCoLC)fst01423772
|
| 655 |
|
7 |
|a Conference papers and proceedings.
|2 lcgft
|
| 655 |
|
7 |
|a Actes de congr�es.
|2 rvmgf
|0 (CaQQLa)RVMGF-000001049
|
| 700 |
1 |
|
|a Agurell, Stig.
|
| 700 |
1 |
|
|a Dewey, William L.
|
| 700 |
1 |
|
|a Willette, Robert E.
|
| 776 |
0 |
8 |
|i Print version:
|a Agurell, Stig.
|t Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects.
|d Oxford : Elsevier Science, �1984
|z 9780120446209
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780120446209
|z Texto completo
|
